Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal ChAdOx1 nCOV-19 in Healthy Adults
NCT04816019Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by University of Oxford. Primary endpoints: Occurrence of solicited signs and symptoms at 7 days, Occurrence of unsolicited signs and symptoms at 28 days and 2 more. Started Apr 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04816019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816019.